Patents by Inventor David V. Sheehan

David V. Sheehan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5601093
    Abstract: A snore-inhibiting device shaped and dimensioned for comfortable installation within the mouth of a user includes a pair of cooperating jaw pieces configured to cap the upper and lower teeth-and-gum structures. The jaw pieces are held together slightly ajar by their integrally molded rearward portions. The small gap between the jaw pieces is enlarged in the frontal area by a rectangular slot through which a tip portion of the tongue can be pushed. The jaw pieces are allowed to separate even more slightly under the pressure of the tongue then to resiliently close back and capture the tip of the tongue, thus keeping the tongue slightly forward from the teeth line. The upper and lower jaw pieces are asymmetrical in order to favor a stable positioning of the device against the lower jaw. The device is made from a thermal plastic having a low melting point so that it may be conformed to the user's dental structure after softening by immersion into boiling water.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: February 11, 1997
    Inventor: David V. Sheehan
  • Patent number: 5558987
    Abstract: A method of treating a patient having a panic disorder, the patient having an elevated CCK peptide plasma level, by lowering the plasma CCK peptide level of the patient. A further method provides a diagnosis of panic disorder in a patient by detecting if that patient's plasma contains elevated CCK peptide levels. A further method determines the efficacy of the drug for the treatment of panic disorder by detecting the ability of the drug to lower elevated CCK peptide levels in a model for panic disorder. Additionally, a method of dosing a patient having elevated CCK peptide levels with an antipanic disorder drug is characterized by administering the drug to a patient and monitoring the lowering of the elevated plasma CCK peptide levels of the patient.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: September 24, 1996
    Assignee: University of South Florida
    Inventors: Thomas N. Thomas, David V. Sheehan, Janet D. Talbot